Abstract:The VEGF (vascular endothelial growth factor) pathway has emerged as an important target for cancer therapy, with VEGF signaling pathway (VSP) inhibitors having been approved for several different malignancies. Less anticipated has been the multitude of cardiovascular and renal effects of these therapies. Hypertension occurs in at least a quarter of patients starting VSP inhibitors, with virtually every patient having an absolute increase in blood pressure. Patients can also develop proteinuria, renal dysfunction, vascular events, or cardiomyopathy. Although these toxicities have been generally manageable, they have introduced cardiovascular and renal considerations for patient care. On the other hand, these sequelae have provided a growing appreciation for the critical role of VEGF in vascular and renal homeostasis in human biology. Although several recent articles have addressed practical considerations with respect to patient care with this class of drugs,1–4 this review will explore mechanisms associated with the vascular toxicities arising from VEGF signaling inhibition in cancer treatment. The human VEGF family consists of 5 related glycoproteins: VEGFA, VEGFB, VEGFC, VEGFD, and PIGF (placental growth factor). These are secreted to form homodimers, which interact with a family of 3 receptor tyrosine kinases: VEGFR1 (VEGF receptor 1), VEGFR2, and VEGFR3 (Figure 1). VEGFA and VEGFB bind to VEGFR1, VEGFA binds to VEGFR2, and VEGFC and VEGFD bind to both VEGFR2 and VEGFR3.1,5 PIGF primarily interacts with VEGFR1. The VEGFRs are found on a wide variety of cell types. VEGFR1, also called Flt-1 (fms-like tyrosine kinase 1), is found on vascular endothelial cells, hematopoietic stem cells, monocytes, and macrophages. VEGFR2, also called KDR (kinase insert domain) or Flk-1 (fetal liver kinase 1), is expressed on vascular and lymphatic endothelial cells; VEGFR3 (also called Flt-4) is restricted to lymphatic endothelial cells.5 On ligand binding, VEGFRs transduce intracellular signals through …

Endocrine Vasculatures Are Preferable Targets of an Antitumor Ineffective Low Dose of Anti-Vegf Therapy.

Endothelial CDS2 deficiency causes VEGFA-mediated vascular regression and tumor inhibition

Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy

Differential Drug Class‐specific Metastatic Effects Following Treatment with a Panel of Angiogenesis Inhibitors

Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor–Associated Hypertension and Vascular Disease

Aflibercept (VEGF Trap): One More Double-Edged Sword of Anti-Vegf Therapy for Cancer?

Potential role of soluble VEGFR-1 in antiangiogenesis therapy for cancer

Vegf-B Is Dispensable For Blood Vessel Growth But Critical For Their Survival, And Vegf-B Targeting Inhibits Pathological Angiogenesis

Non-angiogenic functions of vascular endothelial growth factor]

Discontinuation of Anti-Vegf Cancer Therapy Promotes Metastasis Through a Liver Revascularization Mechanism

Adaptive resistance of tumor cells to anti-vascular endothelial growth factor therapy: A reversible phenomenon

Systemic Overexpression of Angiopoietin-2 Promotes Tumor Microvessel Regression and Inhibits Angiogenesis and Tumor Growth

Discrepancies between antiangiogenic and antitumor effects of recombinant human endostatin.

Anti-angiogenesis Triggers Exosomes Release from Endothelial Cells to Promote Tumor Vasculogenesis.

Antiangiogenesis therapy might have the unintended effect of promoting tumor metastasis by increasing an alternative circulatory system.

Antiangiogenic Agents Are Effective Inhibitors of Endometriosis

VEGF-targeted therapy: mechanisms of anti-tumour activity

Targeting Vegf Pathway To Normalize The Vasculature: An Emerging Insight In Cancer Therapy

Progression of VEGF-targeted cancer therapy

Inhibition Of Tumor-Induced Edema By Antisense Vegf Is Mediated By Suppressive Vesiculo-Vacuolar Organelles (Vvo) Formation

Cardiovascular toxicity induced by anti-VEGF/VEGFR agents: a special focus on definitions, diagnoses, mechanisms and management.